Rui Avelar

Insider Reports History

Reporting-owner location: Vancouver
Latest reporting-owner signature: /s/ Jeffrey J. Plumer, as attorney-in-fact for Rui Avelar
Source: Latest parsed Forms 3/4/5 signature
Transaction source note: Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Reported holdings for Rui Avelar

Form 4 holding Officer

Evolus, Inc.

Security class: Common Stock
Shares / value: 427,423
Estimated value: $2,030,259
Report date: 20 Mar 2026
Price: $4.75
Ownership: Direct

Form 4 holding Officer

Evolus, Inc.

Security class: Performance Restricted Stock Units
Shares / value: 8,802
Estimated value: $258,015
Report date: 16 Mar 2026
Price: $10.85
Ownership: Direct
Underlying class: Common Stock
Underlying amount

Form 4 holding Officer

Evolus, Inc.

Security class: Stock Option (Right to Buy)
Shares / value: 138,649
Estimated value
Report date: 17 Feb 2026
Price
Ownership: Direct
Underlying class: Common Stock
Underlying amount

Insider Reports Filed by Rui Avelar

4 EOLS

Evolus, Inc.

Report period: 20 Mar 2026
Transactions: 1
Transaction value: -$14,815
Accepted by SEC: 20 Mar 2026, 19:19
Role: Officer
Next action: Open filing details

4 EOLS

Evolus, Inc.

Report period: 16 Mar 2026
Transactions: 3
Transaction value: -$146,629
Accepted by SEC: 18 Mar 2026, 20:00
Role: Chief Medical Officer and Head of Research & Development
Next action: Open filing details

4 EOLS

Evolus, Inc.

Report period: 17 Feb 2026
Transactions: 3
Transaction value: $0
Accepted by SEC: 19 Feb 2026, 20:57
Role: Chief Medical Officer and Head of R&D
Next action: Open filing details

4 EOLS

Evolus, Inc.

Report period: 22 Dec 2025
Transactions: 1
Transaction value: -$16,168
Accepted by SEC: 29 Dec 2025, 18:42
Role: Chief Medical Officer & Head of Research and Development
Next action: Open filing details

4 EOLS

Evolus, Inc.

Report period: 12 May 2025
Transactions: 1
Transaction value: -$33,397
Accepted by SEC: 14 May 2025, 19:27
Role: Chief Medical Officer & Head of Research and Development
Next action: Open filing details

4 EOLS

Evolus, Inc.

Report period: 18 Mar 2025
Transactions: 1
Transaction value: -$369,868
Accepted by SEC: 20 Mar 2025, 18:27
Role: Officer
Next action: Open filing details

4 EOLS

Evolus, Inc.

Report period: 07 Mar 2025
Transactions: 3
Transaction value: $0
Accepted by SEC: 11 Mar 2025, 18:54
Role: Chief Medical Officer and Head of R&D
Next action: Open filing details

4 EOLS

Evolus, Inc.

Report period: 23 Dec 2024
Transactions: 1
Transaction value: -$24,438
Accepted by SEC: 26 Dec 2024, 17:28
Role: Chief Medical Officer & Head of Research and Development
Next action: Open filing details

4 EOLS

Evolus, Inc.

Report period: 10 May 2024
Transactions: 1
Transaction value: -$43,761
Accepted by SEC: 14 May 2024, 20:56
Role: Chief Medical Officer & Head of Research and Development
Next action: Open filing details

4 EOLS

Evolus, Inc.

Report period: 19 Mar 2024
Transactions: 1
Transaction value: -$384,350
Accepted by SEC: 21 Mar 2024, 18:09
Role: Chief Medical Officer & Head of Research and Development
Next action: Open filing details

4 EOLS

Evolus, Inc.

Report period: 21 Feb 2024
Transactions: 2
Transaction value: -$23,821
Accepted by SEC: 23 Feb 2024, 20:27
Role: Chief Medical Officer & Head of Research and Development
Next action: Open filing details

4 EOLS

Evolus, Inc.

Report period: 07 Feb 2024
Transactions: 3
Transaction value: $0
Accepted by SEC: 09 Feb 2024, 18:36
Role: Chief Medical Officer and Head of Research & Development
Next action: Open filing details

4 EOLS

Evolus, Inc.

Report period: 14 Aug 2023
Transactions: 2
Transaction value: -$22,707
Accepted by SEC: 16 Aug 2023, 20:25
Role: Chief Medical Officer and Head of Research & Development
Next action: Open filing details

4 EOLS

Evolus, Inc.

Report period: 14 Mar 2023
Transactions: 1
Transaction value: -$126,237
Accepted by SEC: 16 Mar 2023, 19:01
Role: Chief Medical Officer and Head of Research & Development
Next action: Open filing details

4 EOLS

Evolus, Inc.

Report period: 25 Jan 2023
Transactions: 2
Transaction value: $0
Accepted by SEC: 27 Jan 2023, 18:25
Role: Chief Medical Officer and Head of Research & Development
Next action: Open filing details

4 EOLS

Evolus, Inc.

Report period: 08 Mar 2022
Transactions: 1
Transaction value: -$99,121
Accepted by SEC: 10 Mar 2022, 18:23
Role: Chief Medical Officer and Head of Research & Development
Next action: Open filing details

4 EOLS

Evolus, Inc.

Report period: 24 Jan 2022
Transactions: 2
Transaction value: $0
Accepted by SEC: 26 Jan 2022, 20:02
Role: Chief Medical Officer and Head of Research & Development
Next action: Open filing details

4 EOLS

Evolus, Inc.

Report period: 10 Aug 2021
Transactions: 1
Transaction value: -$159,789
Accepted by SEC: 12 Aug 2021, 18:45
Role: Chief Medical Officer and Head of Research & Development
Next action: Open filing details

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. to update or revoke optional consent for future visits. For more information, see our Privacy Policy .